Awaiting development: Guidance and quality standards

Showing 181 to 190 of 344

Guidance and quality standards awaiting development
Title	Type
Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]	Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]	Technology appraisal guidance
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]	Technology appraisal guidance
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]	Technology appraisal guidance
Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692]	Technology appraisal guidance
Obinutuzumab for treating primary membranous nephropathy [ID6751]	Technology appraisal guidance
OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]	Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]	Technology appraisal guidance
Odronextamab for treating relapsed or refractory follicular lymphoma [ID6726]	Technology appraisal guidance
Olezarsen for treating severe hypertriglyceridaemia [GID-TA12016]	Technology appraisal guidance